Beta-containing COVID-19 booster vaccine found to cross-neutralize

$ 23.99

4.6 (687) In stock

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Frontiers T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets

Exploring a variant-adapted SARS-CoV-2 recombinant protein vaccine

Vaccines, Free Full-Text

Discovery of diverse sarbecovirus broadly neutralizing antibodies from SARS-CoV-2 “infected-vaccinated” humans

A case for updating COVID vaccines with beta variant spike sequences

Vaccines that can protect against many coronaviruses could prevent another pandemic

Jean-François Toussaint on LinkedIn: #covid19

A Bivalent Omicron-containing Booster Vaccine Against Covid-19

ACE2 – NIH Director's Blog

Vaccines, Free Full-Text

Latest on Omicron Variant and COVID-19 Vaccine Protection – NIH Director's Blog

Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval - ScienceDirect

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 - ScienceDirect

Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine